Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Labcorp, Personal Genome Diagnostics, Amoy Diagnostics

NEW YORK – Laboratory Corporation of America said this week that it has completed its acquisition of cancer genomics firm Personal Genome Diagnostics for $450 million in cash, with the possibility of $125 million in additional payments based on future performance milestones. Labcorp said the deal will expand its next-generation sequencing oncology portfolio and accelerate development of its liquid biopsy capabilities. The company first announced the purchase in December 2021.

Amoy Diagnostics, Riken Genesis, and Precision Medicine Asia this week submitted an application for approval of the AmoyDx Pan Lung Cancer PCR Panel in Japan as a companion diagnostic to select non-small cell lung cancer patients with ROS1 fusion genes for treatment with Genentech's Rozlytrek (entrectinib), which is marketed in Japan by Chugai Pharmaceutical. The AmoyDx lung cancer panel has already received approval in Japan to screen NSCLC patients for ROS1 gene fusions for treatment with Pfizer's Xalkori (crizotinib).

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.